NEW YORK (GenomeWeb News) –Harvard University spin-out company Auguron Biosciences has licensed its Nucleic Acid Programmable Protein Array (NAPPA) technology to Proteomika, a subsidiary of Progenika Biopharma.
 
Under the agreement, Proteomika may use the NAPPA technology at its facilities for in its autoimmune research and service programs, and it may exercise an option to negotiate an exclusive license to NAPPA within the field of biomarker discovery for inflammatory bowel disease and lupus.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.